Several small-molecular agents that inhibit proangiogenic receptor tyrosine kinases, such as antiangiogenic multityrosine kinase inhibitors (TKIs) like sunitinib, pazopanib, or axitinib, have been widely used for patients with metastatic or recurrent RCC [3]. This evidence concerns the gene NTRK1 and renal cell carcinoma.